Información de Bristol-Myers Squibb Co, dividendo de Bristol-Myers Squibb Co, actividades de los accionistas y más

Más Datos de Bristol-Myers Squibb Co Compañía

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

Información de Bristol-Myers Squibb Co



Símbolo de cotizaciónBMY

Nombre de la empresaBristol-Myers Squibb Co

Fecha de salida a bolsaMar 17, 1980

Director ejecutivoDr. Christopher S. (Chris) Boerner, Ph.D.

Número de empleados34100

Tipo de seguridadOrdinary Share

Fin del año fiscalMar 17

DirecciónRoute 206 And Province Line Road

CiudadPRINCETON

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal08543

Teléfono16092524621

Sitio Webhttps://www.bms.com

Símbolo de cotizaciónBMY

Fecha de salida a bolsaMar 17, 1980

Director ejecutivoDr. Christopher S. (Chris) Boerner, Ph.D.

Ejecutivos de Bristol-Myers Squibb Co



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer

62.72K

-50.00%

Ms. Karin Shanahan

Executive Vice President, Global Product Development & Supply, Member of the Leadership Team

16.70K

+10.70%

Dr. Julia A. Haller, M.D.

Independent Director

13.62K

--

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

12.44K

+87.05%

Ms. Cari Gallman

Executive Vice President, General Counsel and Chief Policy Officer

11.07K

+25.18%

Dr. Manuel Hidalgo Medina, M.D., Ph.D.

Independent Director

--

Mr. Derica W. Rice

Independent Director

--

Ms. Lynelle Hoch

President, Cell Therapy Organization, Member of the Leadership Team

--

Dr. Deepak L. Bhatt, M.D.

Independent Director

--

Mr. Phil Holzer

Senior Vice President, Controller

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Christopher S. (Chris) Boerner, Ph.D.

Chairman of the Board, Chief Executive Officer

62.72K

-50.00%

Ms. Karin Shanahan

Executive Vice President, Global Product Development & Supply, Member of the Leadership Team

16.70K

+10.70%

Dr. Julia A. Haller, M.D.

Independent Director

13.62K

--

Mr. Adam Lenkowsky

Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team

12.44K

+87.05%

Ms. Cari Gallman

Executive Vice President, General Counsel and Chief Policy Officer

11.07K

+25.18%

Dr. Manuel Hidalgo Medina, M.D., Ph.D.

Independent Director

--

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por negocioUSD

Nombre

Ganancia

Proporción

Eliquis

3.68B

30.00%

Opdivo

2.59B

21.09%

Orencia

963.00M

7.85%

Revlimid

838.00M

6.83%

Yervoy

728.00M

5.93%

Otro

3.47B

28.29%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

8.52B

69.44%

International

3.48B

28.37%

other

270.00M

2.20%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Eliquis

3.68B

30.00%

Opdivo

2.59B

21.09%

Orencia

963.00M

7.85%

Revlimid

838.00M

6.83%

Yervoy

728.00M

5.93%

Otro

3.47B

28.29%

Estadísticas de accionistas

Actualizado: mar., 4 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

9.53%

BlackRock Institutional Trust Company, N.A.

4.88%

State Street Investment Management (US)

4.65%

Charles Schwab Investment Management, Inc.

3.48%

JP Morgan Asset Management

3.31%

Otro

74.15%

Accionistas

Proporción

The Vanguard Group, Inc.

9.53%

BlackRock Institutional Trust Company, N.A.

4.88%

State Street Investment Management (US)

4.65%

Charles Schwab Investment Management, Inc.

3.48%

JP Morgan Asset Management

3.31%

Otro

74.15%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

46.45%

Investment Advisor/Hedge Fund

25.61%

Research Firm

2.95%

Pension Fund

2.59%

Bank and Trust

2.29%

Sovereign Wealth Fund

1.75%

Hedge Fund

1.14%

Insurance Company

0.16%

Family Office

0.06%

Otro

16.99%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

4101

1.70B

83.42%

+9.48M

2025Q2

4180

1.70B

83.46%

+31.40M

2025Q1

4287

1.68B

82.63%

+10.66M

2024Q4

4261

1.65B

81.14%

+17.04M

2024Q3

4116

1.60B

78.69%

-22.73M

2024Q2

4105

1.59B

78.35%

-83.12M

2024Q1

4118

1.64B

80.97%

+13.32M

2023Q4

4115

1.60B

78.83%

-46.39M

2023Q3

4042

1.63B

77.83%

-55.50M

2023Q2

4082

1.66B

78.77%

-34.93M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

193.94M

9.53%

+3.47M

+1.82%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

99.37M

4.88%

+1.60M

+1.64%

Jun 30, 2025

State Street Investment Management (US)

94.74M

4.65%

-94.48K

-0.10%

Jun 30, 2025

Charles Schwab Investment Management, Inc.

70.80M

3.48%

+10.20M

+16.82%

Jun 30, 2025

JP Morgan Asset Management

67.41M

3.31%

-2.47M

-3.54%

Jun 30, 2025

Capital International Investors

66.16M

3.25%

-303.34K

-0.46%

Jun 30, 2025

Geode Capital Management, L.L.C.

46.18M

2.27%

+723.46K

+1.59%

Jun 30, 2025

Norges Bank Investment Management (NBIM)

33.57M

1.65%

-1.60M

-4.55%

Jun 30, 2025

Columbia Threadneedle Investments (US)

29.38M

1.44%

+350.53K

+1.21%

Jun 30, 2025

Wellington Management Company, LLP

25.82M

1.27%

+2.09M

+8.83%

Jun 30, 2025

ETFs relacionados



Actualizado: sáb., 1 de nov

Nombre

Proporción

LSV Disciplined Value ETF

83.29%

First Trust NASDAQ Pharmaceuticals ETF

7.02%

VanEck Morningstar Wide Moat Value ETF

4.23%

iShares U.S. Pharmaceuticals ETF

4.22%

VanEck Pharmaceutical ETF

3.69%

Schwab U.S. Dividend Equity ETF

3.66%

Franklin US Dividend Booster Index ETF

3.46%

First Trust Morningstar Dividend Leaders Index Fund

3.11%

Brookstone Value Stock ETF

3.1%

Tema Oncology ETF

3.07%

LSV Disciplined Value ETF

Proporción83.29%

First Trust NASDAQ Pharmaceuticals ETF

Proporción7.02%

VanEck Morningstar Wide Moat Value ETF

Proporción4.23%

iShares U.S. Pharmaceuticals ETF

Proporción4.22%

VanEck Pharmaceutical ETF

Proporción3.69%

Schwab U.S. Dividend Equity ETF

Proporción3.66%

Franklin US Dividend Booster Index ETF

Proporción3.46%

First Trust Morningstar Dividend Leaders Index Fund

Proporción3.11%

Brookstone Value Stock ETF

Proporción3.1%

Tema Oncology ETF

Proporción3.07%

Dividendos



Un total de 22.71B USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Dec 11, 2024

BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option

Jan 03, 2025

Feb 03, 2025

Jan 03, 2025

Sep 10, 2024

BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option

Oct 04, 2024

Nov 01, 2024

Oct 04, 2024

Jun 18, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option

Jul 05, 2024

Aug 01, 2024

Jul 05, 2024

Mar 01, 2024

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option

Apr 05, 2024

May 01, 2024

Apr 04, 2024

Dec 06, 2023

BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option

Jan 05, 2024

Feb 01, 2024

Jan 04, 2024

Sep 20, 2023

BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023

Oct 06, 2023

Nov 01, 2023

Oct 05, 2023

Jun 14, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Aug 01, 2023 going ex on Jul 06, 2023 with reinvestment option

Jul 07, 2023

Aug 01, 2023

Jul 06, 2023

Mar 03, 2023

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on May 01, 2023 going ex on Apr 06, 2023

Apr 10, 2023

May 01, 2023

Apr 06, 2023

Dec 08, 2022

BMY.NB Interim Cash Dividend of gross USD 0.57 paid on Feb 01, 2023 going ex on Jan 05, 2023

Jan 06, 2023

Feb 01, 2023

Jan 05, 2023

Sep 14, 2022

BMY.NB Final Cash Dividend of gross USD 0.54 paid on Nov 01, 2022 going ex on Oct 06, 2022

Oct 07, 2022

Nov 01, 2022

Oct 06, 2022

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos